Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET C2: Neoadjuvant Pembrolizumab in dMMR Colon Cancer
NCT07409844Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colon cancer. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07409844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409844.